Race is on to find protection against HIV transmissions
Global trials are being conducted under the auspices of the HIV Vaccine Trials Network to develop effective vaccines or antibodies
There are an estimated 5000 new HIV transmissions every day. About 70% of the 37-million people living with HIV globally are in sub-Saharan Africa. Of the 1.8- million new HIV transmissions worldwide in 2017, 800,000 occurred in eastern and southern Africa. New, effective prevention strategies are essential to reducing HIV transmission.
So what will it take to reduce HIV transmission? Prevention.
This is why researchers around the world are working hard to find a vaccine that is safe and effective. This requires extensive testing, starting in laboratories and then moving to animal trials. Then comes the crucial human clinical trials. A number of these are under way, running at different sites in 12 countries across four continents.
These trials are being conducted under the auspices of the HIV Vaccine Trials Network. The network runs 49 clinical trial sites in nine countries with 18 ongoing trials, four of which are efficacy trials. Three trials are of particular interest as they have already been running since 2016 and are expected to close in late 2021.